AI Proteins

AI Proteins Raises $41.5 million in Series A

AI Proteins has successfully raised $41.5 million in a Series A at a Undisclosed led by European biotech investors.

Company Overview

AI Proteins is a Biotechnology company headquartered in London UK, founded in 2022 with 60+ employees.

AI Proteins uses artificial intelligence to design novel proteins for therapeutic applications. The company combines computational protein design with experimental validation to create new drug candidates.

Fundraising Details

• Amount Raised: $41.5 million
• Round Type: Series A
• Valuation: Undisclosed
• Date: 2025-11-22
• Investors: European biotech investors and AI-focused venture capital

About AI Proteins

AI Proteins uses artificial intelligence to design novel proteins for therapeutic applications. The company combines computational protein design with experimental validation to create new drug candidates. The company is positioned in the Biotechnology sector, serving a growing market with innovative solutions.

Key Information

• Headquarters: London UK
• Founded: 2022
• Team Size: 60+
• Industry: Biotechnology

What This Means

This funding round demonstrates strong investor confidence in AI Proteins's vision and execution. The capital will likely be used to:

• Scale Operations: Expand the team and operational capacity
• Product Development: Enhance existing products and develop new features
• Market Expansion: Enter new markets and strengthen presence in existing ones
• Technology Investment: Invest in infrastructure and technology capabilities

Industry Context

The Biotechnology sector continues to attract significant investment as companies innovate to meet evolving market demands. AI Proteins's successful fundraising reflects the strong fundamentals and growth potential in this space.

Valuation Milestone

Reaching Undisclosed marks an important milestone for AI Proteins, positioning the company among notable players in the Biotechnology industry.

Looking Ahead

With this new capital, AI Proteins is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotechnology space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.

This fundraising news was reported on 2025-11-22. For more information about AI Proteins, visit their headquarters at London UK.